News

News Subscription

Nov 16. 2021
Basilea announces submission of Investigational New Drug application for novel oncology drug candidate BAL0891
Read more
Download
Oct 11. 2021
Basilea presents preclinical data on synergy between derazantinib and paclitaxel in gastric tumor models at ANE Conference
Read more
Download
Sep 30. 2021 / Ad hoc announcement
Basilea’s partner Asahi Kasei Pharma filed New Drug Application for the marketing authorization of isavuconazole in Japan
Read more
Download
Sep 17. 2021
Basilea presents full safety and efficacy data set on derazantinib in patients with FGFR2 fusion-positive iCCA at ESMO congress
Read more
Download
Aug 17. 2021 / Ad hoc announcement
Basilea reports strong financial results for half-year 2021 with significantly increased cash flow from marketed brands and increases 2021 full-year guidance
Read more
Download
Aug 16. 2021 / Ad hoc announcement
Basilea awarded additional USD 4.3 million by BARDA to support phase 3 development of ceftobiprole
Read more
Download
Jul 29. 2021
Basilea announces U.S. FDA Orphan Drug Designation granted to lisavanbulin for the treatment of malignant glioma
Read more
Download
Jul 26. 2021 / Ad hoc announcement
Basilea’s partner Asahi Kasei Pharma prepares NDA filing for the marketing authorization of isavuconazole in Japan based on positive phase 3 study results
Read more
Download
Jul 14. 2021 / Ad hoc announcement
Basilea announces distribution agreement with JSC Lancet for antibiotic Zevtera® (ceftobiprole) covering Russia and the Eurasian Economic Union
Read more
Download
Jun 07. 2021
Basilea reports new prevalence data for EB1, a potential response-predictive biomarker for lisavanbulin in glioblastoma and other tumor types, at ASCO Annual Meeting
Read more
Download